Skip to Main Content

Author Details

Lloyd J Old
Ludwig Institute for Cancer Research
1959
754
152
PMIDPaper TitleJournal TitlePublished Year
35664317Systems-Level Mapping of Cancer Testis Antigen 1b/a to Sarcoma Pathways Identifies Activated Ran Binding-2 E3 SUMO-Protein Ligase and Transducin-Like Enhancer Protein 1.Front Genet2022
32317292Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.J Immunother Cancer2020
30038035Pillars Article: IFNγ and Lymphocytes Prevent Primary Tumour Development and Shape Tumour Immunogenicity. <i>Nature</i>. 2001. 410: 1107-1111.J Immunol2018
25081390NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus.Int J Cancer2015
26447332Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses.Sci Rep2015
26194713PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer.Eur J Nucl Med Mol Imaging2015
24764581Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells.Cancer Immunol Res2014
22864522Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.Invest New Drugs2013
24045055Process development and production of cGMP grade Melan-A for cancer vaccine clinical trials.Protein Expr Purif2013
24081977Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein.Clin Cancer Res2013
24195083The human cell surfaceome of breast tumors.Biomed Res Int2013
23882157NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma.Cancer Immun2013
23936189Rebmab200, a humanized monoclonal antibody targeting the sodium phosphate transporter NaPi2b displays strong immune mediated cytotoxicity against cancer: a novel reagent for targeted antibody therapy of cancer.PLoS One2013
23390374A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy.Cancer Immun2013
23436617Overcoming regulatory T-cell suppression by a lyophilized preparation of Streptococcus pyogenes.Eur J Immunol2013
23554566A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma.Sarcoma2013
23348793Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma.Mol Imaging2013
21413013Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.Int J Cancer2012
23390371MAGE-A3 is highly expressed in a subset of colorectal cancer patients.Cancer Immun2012
23390370SurfaceomeDB: a cancer-orientated database for genes encoding cell surface proteins.Cancer Immun2012
23032745Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients.Clin Cancer Res2012
22684412A novel cancer/testis antigen KP-OVA-52 identified by SEREX in human ovarian cancer is regulated by DNA methylation.Int J Oncol2012
22847809Phase I clinical trial of mixed bacterial vaccine (Coley's toxins) in patients with NY-ESO-1 expressing cancers: immunological effects and clinical activity.Clin Cancer Res2012
22840835T cell assays and MIATA: the essential minimum for maximum impact.Immunity2012
22923163KP-CoT-23 (CCDC83) is a novel immunogenic cancer/testis antigen in colon cancer.Int J Oncol2012
22437872Antibody therapy of cancer.Nat Rev Cancer2012
22454499Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients.Proc Natl Acad Sci U S A2012
22318866Intracellular tumor-associated antigens represent effective targets for passive immunotherapy.Cancer Res2012
22318521Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.Nature2012
22228793Novel mechanistic insights into arginine deiminase pharmacology suggest 18F-FDG is not suitable to evaluate clinical response in melanoma.J Nucl Med2012
22323448Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma.Blood2012
22427632Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells.J Immunol2012
22109656Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients.Int J Cancer2012
22134507Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase.Br J Cancer2012
21547902Colon cancer associated transcript-1: a novel RNA expressed in malignant and pre-malignant human tissues.Int J Cancer2012
20346054Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.BJU Int2011
22016418Chromosome X-encoded cancer/testis antigens show distinctive expression patterns in developing gonads and in testicular seminoma.Hum Reprod2011
22068895124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET.J Nucl Med2011
22114198Trypanosoma cruzi as an effective cancer antigen delivery vector.Proc Natl Acad Sci U S A2011
22168571Defining the critical hurdles in cancer immunotherapy.J Transl Med2011
21858191Split T cell tolerance against a self/tumor antigen: spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors.PLoS One2011
21764796(124)I-huA33 antibody PET of colorectal cancer.J Nucl Med2011
21933959Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.Proc Natl Acad Sci U S A2011
21565982MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin.Clin Cancer Res2011
21754986MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer.PLoS One2011
21698545Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIXâ¿¢.Cancer Immunol Immunother2011
21318630Expression of the human cancer/testis antigen NY-SAR-35 is activated by CpG island hypomethylation.Biotechnol Lett2011
21315712Antibody inhibiting enzymatic activity of tumour-associated carbonic anhydrase isoform IX.Eur J Pharmacol2011
21365782Expression and purification of cGMP grade NY-ESO-1 for clinical trials.Biotechnol Prog2011
21305280A proteomic analysis of the Pichia pastoris secretome in methanol-induced cultures.Appl Microbiol Biotechnol2011
  • 1 - 50 of 754

Recommended Authors

Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1995
Number of shared co-authors 2
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1991
Number of shared co-authors 1
Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina de Sao Paulo
Career Start Year 1989
Number of shared co-authors 8
Cincinnati Children's Hospital
Career Start Year 1989
Number of shared co-authors 0
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1986
Number of shared co-authors 1
National Cancer Institute, National Institutes of Health (NIH)
Career Start Year 1985
Number of shared co-authors 5
Center for Cancer Research, National Cancer Institute
Career Start Year 1984
Number of shared co-authors 4
Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital
Career Start Year 1984
Number of shared co-authors 2
Technische Universitat Munchen
Career Start Year 1981
Number of shared co-authors 2
University of Nebraska Medical Center
Career Start Year 1980
Number of shared co-authors 0
Center for Computational and Integrative Biology, Massachusetts General Hospital
Career Start Year 1980
Number of shared co-authors 2
Universite de Paris-Cite
Career Start Year 1979
Number of shared co-authors 1
8Benaroya Research Institute
Career Start Year 1978
Number of shared co-authors 2
Purdue University
Career Start Year 1978
Number of shared co-authors 0
Lund University
Career Start Year 1977
Number of shared co-authors 1
University of Virginia School of Medicine
Career Start Year 1976
Number of shared co-authors 1
University Hospital Munster
Career Start Year 1976
Number of shared co-authors 0
Dana-Farber Cancer Institute, Harvard Medical School, Brigham and Women's Hospital
Career Start Year 1976
Number of shared co-authors 2
University of Alabama at Birmingham
Career Start Year 1974
Number of shared co-authors 0
University of California los angeles
Career Start Year 1972
Number of shared co-authors 4
The University of Texas MD Anderson Cancer Center
Career Start Year 1970
Number of shared co-authors 0
Heersink School of Medicine, The University of Alabama at Birmingham
Career Start Year 1970
Number of shared co-authors 1
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1970
Number of shared co-authors 3
The University of Texas MD Anderson Cancer Center
Career Start Year 1968
Number of shared co-authors 10
St. Jude Children's Research Hospital
Career Start Year 1968
Number of shared co-authors 0
National Centre for Asbestos Related Diseases, University of Western Australia
Career Start Year 1967
Number of shared co-authors 4
University of British Columbia
Career Start Year 1965
Number of shared co-authors 0
National Cancer Institute
Career Start Year 1963
Number of shared co-authors 1
University of Colorado School of Medicine
Career Start Year 1961
Number of shared co-authors 6
Monash University
Career Start Year 1958
Number of shared co-authors 0

Collaborators

From Population Health Services (Chen)
Co-authored papers 120
The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Co-authored papers 84
University of Hull
Co-authored papers 27
RIKEN BioResource Research Center
Co-authored papers 22
Columbia University Medical Center Kreitchman PET Center
Co-authored papers 21
Australia Olivia Newton-John Cancer Research Institute, La Trobe University
Co-authored papers 19
New York-Presbyterian Hospital
Co-authored papers 17
Ludwig Institute for Cancer Research Ltd.
Co-authored papers 16
Monash University
Co-authored papers 14
Spanish National Cancer Research Centre-CNIO
Co-authored papers 13
Telethon Kids Institute
Co-authored papers 13
Co-authored papers 11
Co-authored papers 11
Memorial Sloan Kettering Cancer Center
Co-authored papers 9
National Institutes of Health
Co-authored papers 8
Olivia Newton-John Cancer Research Institute
Co-authored papers 8
Memorial Sloan Kettering Cancer Center
Co-authored papers 8
Memorial Sloan Kettering Cancer Center
Co-authored papers 8
Co-authored papers 7
University of Southern California
Co-authored papers 7
Ludwig Institute for Cancer Research, University of California San Diego
Co-authored papers 6
Co-authored papers 6
Genentech Inc.
Co-authored papers 5
Co-authored papers 5
Institute for Frontier Medical Sciences, Kyoto University
Co-authored papers 5
Institute for Systems Biology
Co-authored papers 5
University Hospital Zurich
Co-authored papers 5
CHU de Quebec-Universite Laval
Co-authored papers 4
Washington University School of Medicine
Co-authored papers 4
Memorial Sloan Kettering Cancer Center
Co-authored papers 4